Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

NCT03216070 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Dasatinib 50 MG

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez